Secondary Osteoporosis
Conditions
Brief summary
Changes in the level of P1NP in peripheral blood from baseline to day 7
Detailed description
Changes in the level of CTX in peripheral blood from baseline to day 7 and 14, Changes in the level of P1NP in peripheral blood from baseline to day 14, Changes in GC metabolites in blood from baseline to day 7 (e.g., prednisone levels, and the prednisolone/prednisone ratio), Changes in gene expression in abdominal and gluteal subcutaneous adipose tissue from baseline to day 7 (e.g., adiponectin or visfatin), Changes in gene expression in bone tissue from baseline to day 7 (e.g., RUNX2 or osteocalcin), Changes in insulin secretion and sensitivity from baseline to day 7
Interventions
DRUGPrednisolone 25mg Tablets
DRUGPLACEBO
Sponsors
Odense University Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in the level of P1NP in peripheral blood from baseline to day 7 | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in the level of CTX in peripheral blood from baseline to day 7 and 14, Changes in the level of P1NP in peripheral blood from baseline to day 14, Changes in GC metabolites in blood from baseline to day 7 (e.g., prednisone levels, and the prednisolone/prednisone ratio), Changes in gene expression in abdominal and gluteal subcutaneous adipose tissue from baseline to day 7 (e.g., adiponectin or visfatin), Changes in gene expression in bone tissue from baseline to day 7 (e.g., RUNX2 or osteocalcin), Changes in insulin secretion and sensitivity from baseline to day 7 | — |
Countries
Denmark
Outcome results
None listed